We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
Read MoreHide Full Article
Key Takeaways
Stryker agreed to acquire ZuriMED, adding the commercialized FiberLocker System to its shoulder portfolio.
The FiberLocker System targets a key clinical failure mode linked to rotator cuff repair.
Stryker aims to expand rotator cuff augmentation capabilities across sports medicine and arthroplasty.
Stryker (SYK - Free Report) recently announced a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology designed for rotator cuff augmentation with increased biomechanical strength. The acquisition is aimed at strengthening Stryker’s shoulder portfolio and expanding its ability to support specialists across the continuum of shoulder care.
Per Stryker management, ZuriMED’s technology addresses an important unmet need for shoulder care. The addition of the FiberLocker System is expected to complement Stryker’s existing offerings while reinforcing its focus on advancing innovation and improving patient outcomes.
Likely Trend of SYK Stock Following the News
Following the announcement, SYK shares lost 2.1% at yesterday’s close. Year to date, shares of the company have fallen 7.8% compared with the industry’s 16.3% decline. However, the S&P 500 has risen 11.8% in the same timeframe.
In the long run, the acquisition could support Stryker’s long-term growth by adding a commercialized technology to its existing offerings and potentially increasing its ability to capture demand as rotator cuff procedures expand. The transaction may also create opportunities for deeper relationships with healthcare providers while giving Stryker another avenue to strengthen its position in the competitive sports medicine market.
SYK currently has a market capitalization of $126.84 billion.
Image Source: Zacks Investment Research
More on the News
ZuriMED’s FiberLocker System is a soft tissue augmentation technology designed to address a key clinical failure mode associated with rotator cuff repair. Rotator cuff augmentation is one of the fastest-growing areas within sports medicine and represents a significant opportunity in shoulder care. Through the acquisition, Stryker aims to further strengthen its rotator cuff augmentation capabilities and support shoulder specialists across both sports medicine and arthroplasty.
The transaction remains subject to customary closing conditions. Until the acquisition is completed, Stryker and ZuriMED will continue to operate as separate entities and conduct their businesses as usual.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global rotator cuff repair market is estimated to be valued at $994.1 million in 2026 and is expected to witness a CAGR of 7.6% through 2033.
Factors like the rising incidence of degenerative shoulder disorders among the aging population, advancements in arthroscopic repair techniques and growing adoption of orthobiologics to improve surgical outcomes are supporting market growth.
Other News
In July, Stryker delivered a strong second quarter, with both earnings and sales beating their respective estimates. The quarterly outperformance reflects a solid recovery from the first-quarter cybersecurity disruption. Broad-based strength across MedSurg, Neurotechnology and Orthopedics, coupled with improving production and healthy hospital capital spending, drove the performance. Management tightened its full-year organic growth outlook, signaling confidence in continued operational recovery, which may get partially offset by a temporary supply disruption within the Inari peripheral vascular business.
Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Shutterstock
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
Key Takeaways
Stryker (SYK - Free Report) recently announced a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology designed for rotator cuff augmentation with increased biomechanical strength. The acquisition is aimed at strengthening Stryker’s shoulder portfolio and expanding its ability to support specialists across the continuum of shoulder care.
Per Stryker management, ZuriMED’s technology addresses an important unmet need for shoulder care. The addition of the FiberLocker System is expected to complement Stryker’s existing offerings while reinforcing its focus on advancing innovation and improving patient outcomes.
Likely Trend of SYK Stock Following the News
Following the announcement, SYK shares lost 2.1% at yesterday’s close. Year to date, shares of the company have fallen 7.8% compared with the industry’s 16.3% decline. However, the S&P 500 has risen 11.8% in the same timeframe.
In the long run, the acquisition could support Stryker’s long-term growth by adding a commercialized technology to its existing offerings and potentially increasing its ability to capture demand as rotator cuff procedures expand. The transaction may also create opportunities for deeper relationships with healthcare providers while giving Stryker another avenue to strengthen its position in the competitive sports medicine market.
SYK currently has a market capitalization of $126.84 billion.
Image Source: Zacks Investment Research
More on the News
ZuriMED’s FiberLocker System is a soft tissue augmentation technology designed to address a key clinical failure mode associated with rotator cuff repair. Rotator cuff augmentation is one of the fastest-growing areas within sports medicine and represents a significant opportunity in shoulder care. Through the acquisition, Stryker aims to further strengthen its rotator cuff augmentation capabilities and support shoulder specialists across both sports medicine and arthroplasty.
The transaction remains subject to customary closing conditions. Until the acquisition is completed, Stryker and ZuriMED will continue to operate as separate entities and conduct their businesses as usual.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global rotator cuff repair market is estimated to be valued at $994.1 million in 2026 and is expected to witness a CAGR of 7.6% through 2033.
Factors like the rising incidence of degenerative shoulder disorders among the aging population, advancements in arthroscopic repair techniques and growing adoption of orthobiologics to improve surgical outcomes are supporting market growth.
Other News
In July, Stryker delivered a strong second quarter, with both earnings and sales beating their respective estimates. The quarterly outperformance reflects a solid recovery from the first-quarter cybersecurity disruption. Broad-based strength across MedSurg, Neurotechnology and Orthopedics, coupled with improving production and healthy hospital capital spending, drove the performance. Management tightened its full-year organic growth outlook, signaling confidence in continued operational recovery, which may get partially offset by a temporary supply disruption within the Inari peripheral vascular business.
Stryker Corporation Price
Stryker Corporation price | Stryker Corporation Quote
SYK’s Zacks Rank & Key Picks
Stryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.